Molecular Medicine |
From the Departments of Pharmacology (R.A.K., B.C.O., I.L.O.B.) and Biochemistry (R.A.K., G.A.), University of Nevada School of Medicine, Reno, Nev.
Correspondence to Prof Iain L.O. Buxton, Dept of Pharmacology, MS318, University of Nevada School of Medicine, 1664 N Virginia St, Reno, NV 89557-0046. E-mail buxton@ med.unr.edu
| Abstract |
|---|
|
|
|---|
Key Words: nucleotides cyclodextrin caveolae calcium cholesterol
| Introduction |
|---|
|
|
|---|
When first presented by us in 1983,9 subcellular compartmentation of receptor/G-protein-coupled signaling was not understood. Although the discovery of numerous details of signaling regulation such as kinase anchoring proteins and the role of the cytoskeleton have provided a context for studies of signaling compartments, the discovery of cholesterol-rich regions in the plasma membrane10 and their recognition as signaling domains offers a significant breakthrough in our understanding of how cells organize their response to numerous extracellular stimuli.11,12 Many signaling pathways are now known to be compartmented by caveolae, and to date, associated signaling molecules include bradykinin (BK) receptors,13,14 muscarinic acetylcholine (ACh) receptors,15 receptor tyrosine kinases such as the epidermal growth factor (EGF) receptor,16 and G proteins such as G
q and G
i.17 Of particular relevance to endothelial function, the link between eNOS and the caveolar protein caveolin-1 has implications for vascular regulation. Because endothelial P2Y receptors use NO as their primary effector mediating relaxation,18 and because the caveolin-1/eNOS complex is a key inhibitory regulator of NO production in the endothelium,19 we sought to investigate the hypothesis that P2Y receptors are colocalized in cholesterol-rich membrane microdomains.
Compartmentation of the endothelial response to nucleotides would further our understanding of the Nucleotide Axis Hypothesis, which proposes a framework by which nucleotides act as blood-borne autocrine and paracrine hormones capable of mediating vessel tone on a moment-to-moment basis.2 Our work and that of others has demonstrated that endothelial cells respond to hormonal stimuli20 and shear stress21 by releasing UTP22 and ATP into the vessel lumen. ATP can then act on endothelium at, and downstream from, the site of its release to signal vasodilation at P2Y receptors as ATP per se and again after its metabolism to ADP on the surface of endothelium.2,23 The subsequent regeneration of ATP from ADP on the surface of endothelium by the ecto-nucleoside diphosphate kinase (eNDPK)2,24 propagates vasodilation within the blood vessel by maintaining ATP, and thus ADP, concentrations locally. The eventual metabolism of released ATP to adenosine (ADO) by the time flow reaches resistance vessels further subserves dilation, 2 yielding increased blood flow regionally. The precise role of UTP in the Axis is less well known but intriguing based on its role as a phosphoryl donor in the eNDPK reaction converting ADP to ATP, and its activity at P2Y4.
In this study, we present evidence in guinea pig aorta that nucleotide-mediated endothelial cell calcium mobilization and the resulting relaxation of vascular smooth muscle are sensitive to both the removal of membrane cholesterol by ß-methyl-cyclodextrin (ß-mCD) and the sequestration of cholesterol by filipin. Our results show for the first time that P2Y receptors are functionally compartmented to cholesterol-rich microdomains in GPAECs and that such microdomains act in an agonist-specific manner to increases of intracellular calcium. We suggest a model whereby endothelium may differentiate nucleotide and other stimuli depending on organization and regulation of the microdomain compliment of receptors and their coupling. Furthermore, in an effort to assess the results of ß-mCD treatment of small blood vessel segments (3 to 4 mg wet wt), we detail a rapid and sensitive method for the determination of tissue cholesterol using HPLC.
| Materials and Methods |
|---|
|
|
|---|
Endothelial Cell Isolation and Calcium Imaging
GPAECs were prepared by primary dispersion from dissected aortae7 and grown in culture for 1 week. The maintenance of endothelial phenotype in culture was independently confirmed by flow cytometric analysis of CD31 expression and binding of UEA.2 GPAECs were grown to 25% confluence, washed with a MOPS buffer and loaded with Fura-2 AM (2 µmol/L; Molecular Probes).1,7 Agonists were added by removing 0.5 vol of buffer and replacing it with agonists at 2x in 0.5 vol buffer. This procedure was found to be preferable to either direct concentrated addition or continuous perfusion of agonists because nucleotide responses desensitize rapidly.7 For cholesterol depletion studies, cells were incubated with 5 mmol/L ß-mCD for 1 hour. Control experiments revealed that cultured endothelial cells lose 54±1.1% of their total cholesterol content in the first 20 minutes under these conditions (detection limit 1.5x104 cells). In some experiments, addition of ionomycin followed by Mn2+ served to reference calcium transient size. Precise calibration of intracellular calcium concentrations was neither desirable nor performed.
Cholesterol Determination
Duplicate aortic rings (
4 mg wet wt) were treated with 0, 5, 10, or 15 mmol/L ß-mCD (1 hour 37°C) or 1, 5, 10 mg/L filipin III (30 minutes; 37°C) and extracted with 100 µL of CHCl3 for 2 hours. Tissues were vortexed every 20 minutes to ensure uniform CHCl3 exposure. Rings were withdrawn and the extract dried at 80°C. Residue was resuspended in 100 µL of methanol:acetonitrile 30:70 (v/v) and analyzed by HPLC.26 Briefly, 10 to 20 µL of resuspended, filtered vessel extract was injected onto a C18 column (46x100 mm; 5 µm; 35°C) and eluted over 10 minutes with methanol:acetonitrile 30:70 (v/v). The elution profile (A205) was recorded and standard (retention= 5.5±0.05 minutes) used to construct a standard curve (area under the curve [AUC]) from which unknown cholesterol contents were determined. Spiking of duplicate vessel samples was used to confirm our ability to detect cholesterol in real samples with a limit sensitivity of 300 pg. Amounts of cholesterol were normalized to wet tissue weight.
Tissue Histology
Guinea pig aortae were fixed in 4% paraformaldehyde for 1 hour. Vital dye-stained samples were first incubated at 37°C for 45 minutes in 25 µ mol/L Cell Tracker Green (Molecular Probes) and then fixed. Tissues were infiltrated with a sucrose series in PBS of 5% 1 hour, 15% 4 hours, 15%+7.5% gelatin overnight 37°C. Tissues were embedded in gelatin for cryosectioning at 10 µm on a Leica CM3050 microtome and arranged on glass slides. For hematoxylin/eosin staining, gelatin was melted with PBS (50°C). Slides were fixed in 3% acetic acid in 95% MeOH, tap water rinsed, and stained with hematoxylin and eosin. Vital dye-stained tissues were counterstained with DAPI (4',6-diamidino-2-phenylindole). Slides were dehydrated through an EtOH series and mounted with xylene in Eukitt media (Electron Microscopy Sciences). Both bright-field and fluorescent images were obtained with a Leica DMR microscope and LEI-750 digital camera with Optronics software.
Electron Microscopy
Vessel segments from physiological experiments treated with ß-mCD or control as described above were fixed overnight at 4°C with a solution containing 2.5% glutaraldehyde (v/v), 2.0% paraformaldehyde (wt/vol), and 1.5% sucrose (wt/vol) dissolved in cacodylate buffer (0.1 mol/L, pH 7.3). Samples were washed with cacodylate buffer (0.1 mol/L) containing sucrose (1.5% wt/vol for 1 hour) and postfixed with osmium textroxide (1% wt/vol) for 1 hour. Samples were dehydrated through a graded series of alcohols and embedded in Spurrs low viscosity resin. Ultrathin sections were double stained with alcoholic uranyl acetate and lead citrate and examined with a Philips CMIO transmission electron microscope operating at 80 kV.
Data Analysis
Data from contractile experiments, logged as digital files from QuickLog (Strawberry Tree Software), were normalized by considering baseline tension 0% and peak tension after standard contractile stimulus 100%. Relaxations were then compared as the total reduction from 100% achieved after agonist addition. Averages ±SEM were plotted and analyzed using Prism (GraphPad Software). Calcium data were imported as ratios of measured 510-nm emissions at 340/380-nm excitations for each single-cell region of interest into Prism software and plotted. All observations were performed in triplicate.
Materials
Growth media were from Atlanta Biologicals. TRIzol was from Invitrogen. PECAM1 antibody was from Biogenesis. Fura-2 AM, DAPI, and Cell Tracker Green were from Molecular Probes. All other reagents were from Sigma Chemical Co, including nucleotides, analogs, 2'-deoxy-N6-methyladenosine 3',5'-bisphosphate (MRS2179), filipin III, and ß -methyl-cyclodextrin.
| Results |
|---|
|
|
|---|
|
Nucleotide-Mediated Relaxation Is Sensitive to ß-mCD
Aortic rings contracted with 1 µmol/L NE relaxed to addition of the P2Y1 receptor agonist 2-MeS-ATP (100 nmol/L; Figure 2A). After incubation of the vessel in 15 mmol/L ß-mCD for 1 hour, responsiveness to 2-MeS-ATP is severely compromised (Figure 2B), whereas the control tissue relaxes to P2Y stimulation. Similar results are observed for ATP, ADP (Figure 3A), and UTP (Figure 3B) at 10, 1, and 100 µmol/L, respectively. In all tissues, tension returns to baseline on washout. Isoproterenol (ISO; 10 µmol/L) induced relaxation is insensitive to ß-mCD pretreatment and is similar in both the control and treated tissues (Figure 3B). Total relaxation seen with ISO is additive with the relaxation observed in response to nucleotide agonists like UTP. Contractions observed to 60 mmol/L potassium are not affected by treatment with ß-mCD (not shown).
|
|
Effects of ß-mCD and Filipin Are Concentration-Dependent
With the observation that ß-mCD can reduce the agonist-mediated relaxation observed in guinea pig aorta, we sought to determine if there is a concentration-dependence to the effect of both ß-mCD and filipin to uncouple nucleotide-mediated relaxation. Increasing concentrations of both ß-mCD (5 to 15 mmol/L) and Filipin III (1 to 10 mg/L) reduced aortic relaxations to 100 nmol/L 2-MeS-ATP in NE-stimulated tissues (Figure 4A). The effect of ß-mCD treatment was 5.1±2.0%, 20.8±3.3%, and 62.1±2.7% reductions of relaxation at 5, 10, and 15 mmol/L, respectively, whereas filipin reduced observed relaxations by 17.6±9.9%, 59.4±9.9%, and 100% at 1, 5, and 10 mg/L, respectively (Figure 4B). Using HPLC analysis of matched vessel extracts, we determined that the concentration-dependent effect of ß-mCD to reduce the endothelial-dependent relaxation to nucleotides is paralleled by decreased cholesterol content in the tissues (up to 83.7±6.4%; Figure 4C) after 15 mmol/L ß-mCD treatment. The effects of filipin are not paralleled by reductions of extractable cholesterol content, consistent with cholesterol sequestration rather than depletion.
|
Direct Visualization of the Effects of ß-mCD on Aorta
Treatment with ß-mCD has profound effects on nucleotide-mediated signaling in endothelium. To verify that the endothelium is indeed intact after the ß-mCD treatment, aortic rings from tissue studies were examined (Figure 5). An intact endothelial layer is observed after hematoxylin-eosin staining in both control (Figure 5A) and ß -mCD-treated tissue (Figure 5B). To determine the viability of the endothelial cell layer after ß-mCD treatment, we double labeled aortic rings with DAPI and the vital dye Cell Tracker Green. In these preparations, the GPAECs are capable of sequestering the vital dye in both control (Figure 5C) and ß -mCD-treated (Figure 5D) samples. Treated cells (Figures 5B and 5D), although showing some obvious endothelial disruption, do remain viable despite the absence of relaxation to nucleotides. That ß-mCD depletion of cholesterol selectively depletes signaling microdomains in endothelium is demonstrated by the loss of caveolar structures in endothelial membranes examined under electron microscopy. Micrographs of endothelial membrane in control vessels (Figure 5E) clearly show the presence of caveolae that are rare or absent in samples treated with 15 mmol/L ß-mCD (Figure 5F).
|
ACh and BK Cause Contraction in Cholesterol-Depleted Aorta
Considering the ability of BK to elicit a calcium response in GPAECs regardless of treatment with ß-mCD, we wanted to investigate the functional response to BK in intact vessels. NE-contracted control tissues respond to 1 µmol/L BK with a pronounced relaxation (Figure 6A) similar to that observed in response to P2Y agonists. Aortic rings pretreated with ß-mCD (15 mmol/L) for 1 hour and contracted with NE respond to the same concentration of BK that relaxes control tissues by contracting consistent with a dysfunctional endothelium. The same result is observed in response to 10 µmol/L ACh (Figure 6B). Similar observations are obtained with 10 mg/L filipin (data not shown).
|
Effects of ß-mCD Are Mimicked by MRS-2179 and L-NAME
To further investigate the mechanism of cholesterol depletion on endothelium-dependent relaxation and determine the viability of the endothelial cell layer in our tissues, we compared the responses of tissues in 4 treatment groups: cholesterol depleted (CD), P2Y1 antagonized (MRS2179), eNOS inhibited (L-NAME), and control aortic rings (Figure 7A). P2Y1 receptor-mediated relaxation was specifically antagonized by 3 µmol/L MRS2179 before (5 minutes) NE contraction.6,7 Endothelial NOS was inhibited by treatment of the aorta with 100 µmol/L L-NAME 10 minutes before NE addition. On achieving a stable response to NE, the P2Y1 agonist 2-MeS-ATP was added (100 nmol/L) to each treatment group (Figure 7B). Only the control sample was capable of achieving complete relaxation, whereas the ß-mCD-treated sample displayed a small transient relaxation to 2-MeS-ATP. To determine the functional viability of the endothelium, we added the calcium ionophore A23187 (1 µ mol/L; Figure 7C). Control tissue responded with enhanced relaxation that was only partially additive with the 2-MeS-ATP-induced relaxation, suggesting the NO dependence of both signaling mechanisms. Both the ß-mCD- and MRS2179-treated aortae also relaxed to A23187, indicating that the endothelium is viable and that both perturbations disrupt 2-MeS-ATP signaling upstream of intracellular calcium release. L-NAME treatment blocks the endothelial response to A23187 but not the smooth muscle response (Figure 7C).
|
| Discussion |
|---|
|
|
|---|
Cyclodextrins have been studied for some time as potential carriers for pharmaceuticals31 and their ability to incorporate cholesterol has proven to be of great utility. The specific role of ß-mCD in the removal of plasmalemmal cholesterol has been well characterized.32 Cytotoxicity assays using different cyclodextrins demonstrate that ß-mCD is nontoxic at concentrations higher and exposures longer than those used here. Exposure to 20 mmol/L ß-mCD for 2 hours was shown to remove up to 90% of the cholesterol from mouse L cells without detectable adenine release.32 Our own results with cultured guinea pig endothelial cells show that exposure to 5 mmol/L for 20 minutes removes 54% of cholesterol measured by HPLC. Repletion of cholesterol with sterol-loaded cyclodextrins has been shown to re-establish inositol phosphate signaling in response to BK and EGF in systems where cholesterol was previously removed by empty cyclodextrin.16 This approach was ineffective in our studies (data not shown). Microscopic examination of control and ß-mCD-treated aortic rings using hematoxylin-eosin staining (Figures 5A and 5B) demonstrates altered morphology of the endothelial lining in cyclodextrin-treated tissues. Control endothelium is seen as a contiguous monolayer across the basement membrane, whereas the cholesterol-depleted endothelium presents as discrete cells, partially withdrawn from each other. The apparent partial endothelial disruption notwithstanding, vital dye demonstrates that the endothelial cells in these ß-mCD-treated tissues are viable (Figures 5B and 5C). Furthermore, detailed examination of the endothelium under electron microscopy reveals that caveolar structures are absent in ß-mCD-treated tissues. These data are consistent with the notion that ß-mCD renders the endothelium dysfunctional.
Despite the altered morphology of ß-mCD-treated endothelium in guinea pig aorta, addition of A23187 first causes relaxation of vessel tone while vessels mechanically denuded of endothelium contract to A23187 (not shown). Thus, even with a dysfunctional endothelium, under these experimental conditions, one does not see immediate effects of A23187 directly on the smooth muscle. The subsequent contraction of all vessels to A23187 no matter their prior treatment confirms the action of the ionophore on the vascular smooth muscle and suggests probable depletion of endothelial NO after approximately 2 minutes. In control tissues where eNOS substrates have likely been depleted by prolonged NO signaling, or where eNOS is specifically inhibited by L-NAME pretreatment, the kinetics of contraction are rapid (Figure 7A). In aortic rings where P2Y receptor signaling to eNOS has been prevented by ß-mCD or MRS2179 pretreatment, the apparent kinetics of contraction to A23187 are attenuated.
There is an interesting distinction between depletion of membrane cholesterol and removal of caveolin. The caveolin-1 knockout mouse demonstrates enhanced responsiveness to ACh over wild-type mice.29 In the present study, we report the complete absence of vascular relaxation in response to ACh in ß-mCD-treated tissues. Using transmission electron microscopy, Drab et al29 demonstrate that endothelial cell caveolae are disrupted in caveolin-1 knockouts, eliminating the possibility that other caveolins can compensate for the loss. Taken together, these observations are consistent with the growing body of evidence that the association of caveolin-1 and eNOS inhibits NO formation.15,33 In caveolin-1 knockouts, eNOS cannot form an inhibitory complex with caveolin-1. This may allow increased NO production in response to ACh stimulation of contracted vessels. The direct association of receptor and eNOS is not likely given that eNOS activation is downstream of intracellular calcium release and not directly coupled to binding of ligand to receptor.
In our studies, eNOS is likely to be physically separated from receptor molecules in response to the disruption of caveolae (Figure 8). More importantly, the effect of ß-mCD treatment uncouples receptor responses in a complex fashion. Although BK still causes the release of intracellular calcium in the endothelial cell, its ability to relax the vessel is lost. P2Y agonists on the other hand are neither able to raise intracellular calcium nor elicit relaxation. Such data suggest that signaling microdomains are able to respond to calcium activation of eNOS in a cholesterol-dependent fashion (Figure 8). These observations along with both the established inhibition of eNOS by caveolin and the activation of eNOS by calcium/calmodulin, lead to an intriguing hypothetical role for caveolae as receptor-specific calcium-sensing domains. It is possible to suggest that BK stimulation, unlike that of nucleotides, raises calcium without an effect of ß-mCD treatment because in GPAECs the BK receptor is neither prelocalized to nor entirely dependent on the caveolar domain, whereas nucleotide receptors are. Support for this notion comes from studies showing that BK receptors move to cholesterol-rich signaling domains after stimulation.14,16 Despite such compartmentation of receptors, the ß-mCD-treated cells still do not respond to BK-mediated increases in calcium with production of NO as might be expected if calcium has access to eNOS. The notion that agonist-specific compartmentation can extend beyond receptor localization is supported by the fact that global elevation of calcium, as occurs after A23187, produces endothelial-dependent relaxation not unlike controls. The large calcium elevation seen after BK stimulation of ß -mCD-treated GPAECs (Figure 1B) does not equate to relaxation in ß-mCD-treated tissues. Our data are consistent with the possibility that the caveolin-1:eNOS inhibitory complex cannot be overcome by agonist-mediated calcium elevation in the absence of cholesterol and/or cholesterol-dependent microdomain organization.
|
Nucleotide receptors must now be added to the list of signaling initiators associated with cholesterol-rich signaling microdomains. The association of these receptors with caveolae and/or DIGs suggests a potential paradigm for recognition of different nucleotides by endothelium under disparate conditions or anatomical locations. Endothelial cells may organize different P2Y receptors into different signaling domains in order to distinguish stimuli and regulate coupling to second messengers. When placed in the general context of local events occurring in blood vessels and the specific context offered by the Nucleotide Axis Hypothesis in particular, the regulation of nucleotide signaling offers increased understanding of vascular biology and possible future therapeutic targets for the treatment of cardiovascular disease.
| Acknowledgments |
|---|
Received April 19, 2002; revision received June 13, 2002; accepted July 10, 2002.
| References |
|---|
|
|
|---|
2. Buxton ILO, Kaiser RA, Oxhorn BC, Cheek DJ. Evidence supporting the nucleotide axis hypothesis: ATP release and metabolism by coronary endothelium. Am J Physiol. 2001; 281: H1657H1666.
3. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998; 50: 413492.
4. Boarder MR, Hourani SM. The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. Trends Pharmacol Sci. 1998; 19: 99107.[CrossRef][Medline] [Order article via Infotrieve]
5. Communi D, Janssens R, Suarez-Huerta N, Robaye B, Boeynaems JM. Advances in signalling by extracellular nucleotides. the role and transduction mechanisms of P2Y receptors. Cell Signal. 2000; 12: 351360.[CrossRef][Medline] [Order article via Infotrieve]
6. Kaiser RA, Buxton IL. Endothelium-dependent, MRS2179-independent actions of uridine 5'-triphosphate in guinea pig aorta. Proc West Pharmacol Soc. 2001; 44: 4951.[Medline] [Order article via Infotrieve]
7. Kaiser RA, Buxton IL. Nucleotide-mediated relaxation in guinea-pig aorta: selective inhibition by MRS2179. Br J Pharmacol. 2002; 135: 537545.[CrossRef][Medline] [Order article via Infotrieve]
8. von Kugelgen I, Wetter A. Molecular pharmacology of P2Y-receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000; 362: 310323.[CrossRef][Medline] [Order article via Infotrieve]
9. Buxton ILO, Brunton LL. Compartments of cyclic-AMP and protein-kinase in mammalian cardiomyocytes. J Biol Chem. 1983; 258: 233239.
10. Zajchowski LD, Robbins SM. Lipid rafts and little caves. Eur J Biochem. 2002; 269: 737752.[Medline] [Order article via Infotrieve]
11. Anderson RG. The caveolae membrane system. Annu Rev Biochem. 1998; 67: 199225.[CrossRef][Medline] [Order article via Infotrieve]
12. Ostrom RS. New determinants of receptor-effector coupling: trafficking and compartmentation in membrane microdomains. Mol Pharmacol. 2002; 61: 473476.
13. Haasemann M, Cartaud J, Muller-Esterl W, Dunia I. Agonist-induced redistribution of bradykinin B2 receptor in caveolae. J Cell Sci. 1998; 111: 917928.[Abstract]
14. Sabourin T, Bastien L, Bachvarov DR, Marceau F. Agonist-induced translocation of the kinin B1 receptor to caveolae-related rafts. Mol Pharmacol. 2002; 61: 546553.
15. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, Sessa WC. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 2000; 6: 13621367.[CrossRef][Medline] [Order article via Infotrieve]
16. Pike LJ, Miller JM. Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover. J Biol Chem. 1998; 273: 2229822304.
17. De Weerd WF, Leeb-Lundberg LM. Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled G
subunits G
q and G
i in caveolae in DDT1 MF-2 smooth muscle cells. J Biol Chem. 1997; 272: 1785817866.
18. Dol-Gleizes F, Mares AM, Savi P, Herbert JM. Relaxant effect of 2-methyl-thio-adenosine diphosphate on rat thoracic aorta: effect of clopidogrel. Eur J Pharmacol. 1999; 367: 247253.[CrossRef][Medline] [Order article via Infotrieve]
19. Dessy C, Kelly RA, Balligand JL, Feron O. Dynamin mediates caveolar sequestration of muscarinic cholinergic receptors and alteration in NO signaling. EMBO J. 2000; 19: 42724280.[CrossRef][Medline] [Order article via Infotrieve]
20. Yang S, Cheek DJ, Westfall DP, Buxton IL. Purinergic axis in cardiac blood vessels: agonist-mediated release of ATP from cardiac endothelial cells. Circ Res. 1994; 74: 401407.
21. Bodin P, Burnstock G. ATP-stimulated release of ATP by human endothelial cells. J Cardiovasc Pharmacol. 1996; 27: 872875.[CrossRef][Medline] [Order article via Infotrieve]
22. Lazarowski ER, Homolya L, Boucher RC, Harden TK. Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem. 1997; 272: 2434824354.
23. Harden TK, Lazarowski ER, Boucher RC. Release, metabolism and interconversion of adenine and uridine nucleotides: implications for G protein-coupled P2 receptor agonist selectivity. Trends Pharmacol Sci. 1997; 18: 4346.[Medline] [Order article via Infotrieve]
24. Lazarowski ER, Homolya L, Boucher RC, Harden TK. Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J Biol Chem. 1997; 272: 2040220407.
25. McGookey DJ, Fagerberg K, Anderson RGW. Filipin-cholesterol complexes form in uncoated vesicle membrane derived from coated vesicles during receptor-mediated endocytosis of low density lipoprotein. J Cell Biol. 1983; 96: 12731278.
26. Lopez-Hernandez, J, Gonzalez-Castro MJ, Pineiro-Sotelo M. Determination of sterols in sea urchin gonads by high-performance liquid chromatography with ultraviolet detection. J Chromatogr Sci. 1999: 37: 237239.
27. Parton RG, Simons K. Digging into caveolae. Science. 1995; 269: 13981399.
28. Darblade B, Caillaud D, Poirot M, Fouque M, Thiers JC, Rami J, Bayard F, Arnal JF. Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta. Cardiovasc Res. 2001; 50: 566576.
29. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001; 293: 24492452.
30. Luscher TF, Boulanger CM, Yang Z, Noll G, Dohi Y. Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. Circulation. 1993; 87 (suppl V): V36V37.Abstract.
31. Pitha J, Irie T, Sklar PB, Nye JS. Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci. 1988; 43: 493502.[CrossRef][Medline] [Order article via Infotrieve]
32. Kilsdonk EP, Yancey PG, Stoudt GW, Bangerter FW, Johnson WJ, Phillips MC, Rothblat GH. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem. 1995; 270: 1725017256.
33. Everson WV, Smart EJ. Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med. 2001; 11: 246250.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
Y. C. Ruan, Z. Wang, J. Y. Du, W. L. Zuo, J. H. Guo, J. Zhang, Z. L. Wu, H. Y. Wong, Y. W. Chung, H. C. Chan, et al. Regulation of smooth muscle contractility by the epithelium in rat vas deferens: role of ATP-induced release of PGE2 J. Physiol., October 15, 2008; 586(20): 4843 - 4857. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Linder, K. M. Thakali, J. M. Thompson, S. W. Watts, R. C. Webb, and R. Leite Methyl-beta-cyclodextrin Prevents Angiotensin II-Induced Tachyphylactic Contractile Responses in Rat Aorta J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 78 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Yegutkin, A. Mikhailov, S. S. Samburski, and S. Jalkanen The Detection of Micromolar Pericellular ATP Pool on Lymphocyte Surface by Using Lymphoid Ecto-Adenylate Kinase as Intrinsic ATP Sensor Mol. Biol. Cell, August 1, 2006; 17(8): 3378 - 3385. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Linder, R. Leite, K. Lauria, T. M. Mills, and R. C. Webb Penile erection requires association of soluble guanylyl cyclase with endothelial caveolin-1 in rat corpus cavernosum Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2006; 290(5): R1302 - R1308. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Linder, L. P. McCluskey, K. R. Cole III, K. M. Lanning, and R. C. Webb Dynamic Association of Nitric Oxide Downstream Signaling Molecules with Endothelial Caveolin-1 in Rat Aorta J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 9 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stirone, A. Boroujerdi, S. P. Duckles, and D. N. Krause Estrogen Receptor Activation of Phosphoinositide-3 Kinase, Akt, and Nitric Oxide Signaling in Cerebral Blood Vessels: Rapid and Long-Term Effects Mol. Pharmacol., January 1, 2005; 67(1): 105 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. L. O. Buxton Regulation of Uterine Function: a Biochemical Conundrum in the Regulation of Smooth Muscle Relaxation Mol. Pharmacol., May 1, 2004; 65(5): 1051 - 1059. [Abstract] [Full Text] |
||||
![]() |
E.-M. Hur, Y.-S. Park, B. D. Lee, I. H. Jang, H. S. Kim, T.-D. Kim, P.-G. Suh, S. H. Ryu, and K.-T. Kim Sensitization of Epidermal Growth Factor-induced Signaling by Bradykinin Is Mediated by c-Src: IMPLICATIONS FOR A ROLE OF LIPID MICRODOMAINS J. Biol. Chem., February 13, 2004; 279(7): 5852 - 5860. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Henttinen, S. Jalkanen, and G. G. Yegutkin Adherent Leukocytes Prevent Adenosine Formation and Impair Endothelial Barrier Function by Ecto-5'-nucleotidase/CD73-dependent Mechanism J. Biol. Chem., June 27, 2003; 278(27): 24888 - 24895. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Joseph, M. R. Buchakjian, and G. R. Dubyak Colocalization of ATP Release Sites and Ecto-ATPase Activity at the Extracellular Surface of Human Astrocytes J. Biol. Chem., June 20, 2003; 278(26): 23331 - 23342. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |